stocksbrew

Amneal PharmaceuticalsAMRX

Buy more

Buy more on a dip to our buy price, which is under Friday's $21.

  • 8 good· Earnings beat
  • 3 to watch· Revenue slowing

$21.13−0.26 (−1.22%)

After hours $21.78 +3.2% · 6:11 PM ET on Friday

Price at 3:59 PM ET on Friday

Market closed · opens in 22h 24mNext open: Monday, Nov 23, 9:30 AM ET

NYSE · Healthcare · Health Care · Mid-size company

The price we'd buy AMRX at comes with a free account

It also has the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.

What would change it

Sources

Could move it to Keep

Next report

  • Shrinking

    sales

Compared with the S&P 500

  • 9 points

    worse in one day

  • 21 points

    worse in five trading days

+83.5% in a year

Earnings report

The news behind our call

written Sep 22, 10:07 AM ETSep 22, 10:07 AM ET · 1 articles · 1 sources
  • FDA approval lets Amneal sell generic lanreotide immediately.

How AMRX's risks changed

What changed

  1. Tuesday
  2. Amneal announces European approval of Adcomfo® (Omalizumab)

  3. Nov 13
  4. Has Amneal Pharmaceuticals got too expensive on earnings?

  5. Nov 10
  6. Amneal Named BioSpace 2027 best Place to work

  7. Nov 3
  8. AMRX reported earnings

    Earnings

  9. Sep
  10. Analyst ratings shifted: 2 more buy

    Analysts

  11. Aug
  12. Analyst ratings shifted: 1 more buy

    Analysts

Overview

Key figures

Revenue (TTM)
$3.2B
Revenue growth, 1 year
+8.9%
Net income
$133M
EPS (diluted)
$0.40
Gross margin
40.0%
Operating margin
16.7%
Return on equity
70.0%
Return on capital
15.4%
Debt / equity
5.12
Current ratio
1.87
Buyback yield
-4.13%

Key facts

Company value
$7.4B
Price / last year's earnings
52.8×
Today's range
21.0721.70
Past year's range
11.8121.88
Yesterday's close
$21.39
Swings vs the market
1.3×about the same
Weekend

Still Sunday. Nothing's moving except the clock.

22hrs24min16sec

Market opens Monday, Nov 23 at 9:30 AM ET